Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Vollmer

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 17, 2005
Validation of the NARCOMS Registry: pain assessmentRuth Ann Marrie, Gary Cutter, Tuula Tyry, et al.
The Journal of Nervous and Mental Disease|June 17, 2008
Physical activity correlates with neurological impairment and disability in multiple sclerosisRobert W Motl, Erin M Snook, Daniel R Wynn, et al.
Archives of Physical Medicine and Rehabilitation|May 15, 2012
The symptom inventory disability-specific short forms for multiple sclerosis: construct validity, responsiveness, and interpretationCarolyn E Schwartz, Rita K Bode, Brian R Quaranto, et al.
Neuroepidemiology|November 13, 2008
Smoking status over two years in patients with multiple sclerosisRuth Ann Marrie, Gary Cutter, Tuula Tyry, et al.
Neurorehabilitation|December 29, 2009
Age-related comparisons of people with multiple sclerosis: demographic, disease, and treatment characteristicsRobert J Buchanan, Bonnie J Chakravorty, Tuula Tyry, et al.
CNS Drugs|November 9, 2022
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple SclerosisLéorah Freeman, Erin E Longbrake, Patricia K Coyle, et al.
Journal of Neuropathology and Experimental Neurology|June 20, 2012
Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumabB K Kleinschmidt-DeMasters, Augusto Miravalle, Jeffrey Schowinsky, et al.
Neuroepidemiology|February 2, 2011
Smokers with multiple sclerosis are more likely to report comorbid autoimmune diseasesRuth Ann Marrie, Ralph I Horwitz, Gary Cutter, et al.
Clinical Drug Investigation|May 31, 2007
Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric ModelClaude Lepen, Patricia Coyle, Timothy Vollmer, et al.
Multiple Sclerosis and Related Disorders|April 12, 2016
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trialGlenn Phillips, Shien Guo, Randall Bender, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 17, 2005
Validation of the NARCOMS Registry: pain assessmentRuth Ann Marrie, Gary Cutter, Tuula Tyry, et al.
The Journal of Nervous and Mental Disease|June 17, 2008
Physical activity correlates with neurological impairment and disability in multiple sclerosisRobert W Motl, Erin M Snook, Daniel R Wynn, et al.
Archives of Physical Medicine and Rehabilitation|May 15, 2012
The symptom inventory disability-specific short forms for multiple sclerosis: construct validity, responsiveness, and interpretationCarolyn E Schwartz, Rita K Bode, Brian R Quaranto, et al.
Neuroepidemiology|November 13, 2008
Smoking status over two years in patients with multiple sclerosisRuth Ann Marrie, Gary Cutter, Tuula Tyry, et al.
Neurorehabilitation|December 29, 2009
Age-related comparisons of people with multiple sclerosis: demographic, disease, and treatment characteristicsRobert J Buchanan, Bonnie J Chakravorty, Tuula Tyry, et al.
CNS Drugs|November 9, 2022
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple SclerosisLéorah Freeman, Erin E Longbrake, Patricia K Coyle, et al.
Journal of Neuropathology and Experimental Neurology|June 20, 2012
Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumabB K Kleinschmidt-DeMasters, Augusto Miravalle, Jeffrey Schowinsky, et al.
Neuroepidemiology|February 2, 2011
Smokers with multiple sclerosis are more likely to report comorbid autoimmune diseasesRuth Ann Marrie, Ralph I Horwitz, Gary Cutter, et al.
Clinical Drug Investigation|May 31, 2007
Long-Term Cost Effectiveness of Interferon-beta-1a in the Treatment of Relapsing-Remitting Multiple Sclerosis : An Econometric ModelClaude Lepen, Patricia Coyle, Timothy Vollmer, et al.
Multiple Sclerosis and Related Disorders|April 12, 2016
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trialGlenn Phillips, Shien Guo, Randall Bender, et al.
Pageof 8